The Father!
Taylor Morrison Home
TMHC
D.R. Horton
DHI
Adobe
ADBE
Meritage Homes
MTH
Meta Platforms
META
US Stock MarketDetailed Quotes
LGVN Longeveron
- 1.760
- +0.050+2.92%
Close Mar 20 16:00 ET
- 1.760
- 0.0000.00%
Post 19:13 ET
26.27MMarket Cap-0.67P/E (TTM)
1.880High1.680Low628.29KVolume1.700Open1.710Pre Close1.14MTurnover4.98%Turnover RatioLossP/E (Static)14.93MShares6.40052wk High1.20P/B22.21MFloat Cap0.77152wk Low--Dividend TTM12.62MShs Float450.000Historical High--Div YieldTTM11.70%Amplitude0.770Historical Low1.813Avg Price1Lot Size
Longeveron Stock Forum
Sign in to post a comment
$Longeveron (LGVN.US)$ are people getting in at ground zero now?
1
$Longeveron (LGVN.US)$
Breakthrough: FDA Fast-Tracks Novel Cell Therapy for Alzheimer's Treatment - Longeveron Secures Major Regulatory Win
Breakthrough: FDA Fast-Tracks Novel Cell Therapy for Alzheimer's Treatment - Longeveron Secures Major Regulatory Win
$Longeveron (LGVN.US)$ Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced the positive outcome of a Type B meeting with the U.S. Food and Drug Administration (FDA), supporting the advancement of laromestrocel (Lomecel-BTM), a proprietary, scalable, allogeneic, investigational cellular therapy, as a potential treatment for Alzheimer's disease (AD)....
$Longeveron (LGVN.US)$
Longeveron® Announces Positive Type B Meeting with U.S. FDA Regarding Pathway to BLA for Laromestrocel (Lomecel-BTM) in Alzheimer's Disease
Thursday, 20th March at 9:00 am
Planned single, pivotal Phase 2/3 clinical trial, if positive, acceptable for Biological License Application (BLA) submission for Alzheimer's disease
Alignment with FDA on proposed trial study design, population and endpoints
Initiation of planned pivotal Phase 2/3 clinical trial anticipated in 2H 20...
Longeveron® Announces Positive Type B Meeting with U.S. FDA Regarding Pathway to BLA for Laromestrocel (Lomecel-BTM) in Alzheimer's Disease
Thursday, 20th March at 9:00 am
Planned single, pivotal Phase 2/3 clinical trial, if positive, acceptable for Biological License Application (BLA) submission for Alzheimer's disease
Alignment with FDA on proposed trial study design, population and endpoints
Initiation of planned pivotal Phase 2/3 clinical trial anticipated in 2H 20...
2
$Longeveron (LGVN.US)$
Target Price ...10
Target Price ...10
2
1
NOTE!
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release;...
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release;...
47
8
1
$Longeveron (LGVN.US)$
The CLEAR MIND trial results highlight the potential of cell-based therapy as a novel approach to Alzheimer's disease treatment. What distinguishes laromestrocel is its multi-modal mechanism - addressing vascular function, immune modulation, and tissue repair simultaneously - contrasting with single-target approaches that have historically shown success.
The cognitive benefits observed across multiple measures suggest real-world meaningful effects. The...
The CLEAR MIND trial results highlight the potential of cell-based therapy as a novel approach to Alzheimer's disease treatment. What distinguishes laromestrocel is its multi-modal mechanism - addressing vascular function, immune modulation, and tissue repair simultaneously - contrasting with single-target approaches that have historically shown success.
The cognitive benefits observed across multiple measures suggest real-world meaningful effects. The...
No comment yet
Market Insights
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Sean Parker : ive been in for a couple weeks waiting on the market to catch up.